BridgeMD
Eptinezumab as Preventive Treatment of Migraine in Adults with Migraine
EU CTIS ID: 2023-510183-12-00
What this study is testing
This study evaluates the efficacy of eptinezumab to prevent migraine in participants with chronic migraine.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • The participant has a diagnosis of CM as defined by IHS ICHD-3 guidelines confirmed at screening visit with a history of migraine onset at least 12 months prior to the Screening Visit. • The participant has had a diagnosis of migraine at <50 years of age. • The participant has ≥8 migraine days per month for each month within the past 3 months prior to the Screening Visit. • The participant fulfils the following criteria for migraine in prospectively collected information in the eDiary during the screening period: • Migraine occurring on ≥8 days and headache occurring on ≥15 to ≤26 days. • The participant has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days following the Screening Visit. • The participant is aged ≥18 (≥20 for Taiwan) and ≤75 years at the Screening Visit. Other inclusion criteria may apply
You likely can't join if
- • The participant has received any medication targeting the calcitonin generelated peptide (CGRP) pathway as preventive treatment of migraine. • The participant has confounding and clinically significant pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome). • The participant has a diagnosis of acute or active temporomandibular disorder. • The participant has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), ophthalmoplegic migraine, migraine with brainstem aura and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration). • The participant has a lifetime history of psychosis, bipolar mania, or dementia. • Participants with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to screening are also excluded. • The participant has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism). Other exclusion criteria may apply
The study team makes the final eligibility decision.
Where it's taking place
- Taiwan
- Japan
- Georgia
- China
- Korea, Republic of
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taiwan; Japan; Georgia; China; Korea, Republic of. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.